Literature DB >> 12445739

Quantification of T-cell receptor excision circle DNA using fluorescence resonance energy transfer and the LightCycler system.

Juergen Loeffler1, Ralf Bauer, Holger Hebart, Daniel C Douek, Georg Rauser, Peter Bader, Hermann Einsele.   

Abstract

T-cell receptor excision circles (TRECs) are circular, stable extrachromosomal DNA fragments and are generated during V(D)J gene recombination, a process responsible for diversity of the T-cell receptor repertoire. Here we describe a sensitive, rapid and easy to perform real-time PCR assay based on the LightCycler technique for the quantification of TRECs among peripheral blood cells and a comparison of this assay with conventional PCR-ELISA. By LightCycler, a sensitivity of 20 copies of plasmid deltaRec-psiJalpha Signal Joint TREC DNA was achieved whereas by PCR-ELISA, a detection limit of 2 copies was demonstrated. In blood samples from healthy individuals (n=52) a median TREC count of 1.6x10(4) copies [range 2x10(1) to 2x10(5)]/2x10(5) peripheral blood mononuclear cells (PBMNCs) and in cord blood, a median TREC count of 1.45x10(5) copies [range 1.2x10(5) to 1.6x10(5)]/2x10(5) PBMNCs) could be detected. No significant difference was found in 15 individuals when unfractionated PBMNCs (median count of 1.1x10(5) copies/2x10(5) PBMNCs) or magnetic associated cell sorter (MACS)-sorted CD45RA+ T-cells (median count of 2.5x10(5) copies/2x10(5) cells) were analyzed for TREC counts. In addition, we examined the number of deltaRec-psiJalpha Signal Joint TREC in paediatric (n=6) and adult patients (n=7) after allogeneic stem cell transplantation. In children, we observed a median TREC count of 5.7x10(4) copies/2x10(5) PBMNCs after 1x10(4) and 5.6x10(4) copies/2x10(5) PBMNCs after 2 years, and in adults, a median count of 3.6x10(4) copies/2x10(5) PBMNCs after 1x10(4) and 1.1x10(4) copies/2x10(5) PBMNCs after 2 years. In conclusion, the LightCycler-based real-time PCR assay described offers a very sensitive and rapid tool for the quantification of TREC DNA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445739     DOI: 10.1016/s0022-1759(02)00337-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation.

Authors:  Onder Alpdogan; Stephanie J Muriglan; Jeffrey M Eng; Lucy M Willis; Andrew S Greenberg; Barry J Kappel; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

2.  Tracing thymic output in older individuals.

Authors:  W A Mitchell; P O Lang; R Aspinall
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

3.  Umbilical cord-derived mesenchymal stem cells regulate thymic epithelial cell development and function in Foxn1(-/-) mice.

Authors:  Guangyang Liu; Lihua Wang; Tianxiang Pang; Delin Zhu; Yi Xu; Hanyu Wang; Xiuli Cong; Yongjun Liu
Journal:  Cell Mol Immunol       Date:  2014-02-24       Impact factor: 11.530

4.  Relationship between antithymocyte globulin, T cell phenotypes, and clinical outcomes in pediatric kidney transplantation.

Authors:  Brian I Shaw; Hui-Jie Lee; Cliburn Chan; Robert Ettenger; Paul Grimm; Meghan Pearl; Elaine F Reed; Mark A Robien; Minnie Sarwal; Linda Stempora; Barry Warshaw; Congwen Zhao; Olivia M Martinez; Allan D Kirk; Eileen T Chambers
Journal:  Am J Transplant       Date:  2020-09-12       Impact factor: 8.086

5.  FK506 attenuates thymic output in patients with myasthenia gravis.

Authors:  Takao Mitsui; Yukiko Kuroda; Shu-Ichi Ueno; Naoko Matsui; Ryuji Kaji
Journal:  Arch Med Sci       Date:  2013-12-26       Impact factor: 3.318

Review 6.  T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome.

Authors:  Ahmed Gaballa; Mikael Sundin; Arwen Stikvoort; Muhamed Abumaree; Mehmet Uzunel; Darius Sairafi; Michael Uhlin
Journal:  Int J Mol Sci       Date:  2016-10-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.